



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

JAN - 5 1999

Charles E. Van Horn  
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.  
1300 I Street, N.W.  
Washington, D.C. 20005-3315


In re NeXstar Pharmaceuticals, Inc. : DISMISSAL OF PATENT  
U.S. Patent No. 5,435,989 : TERM EXTENSION  
: APPLICATION

An application for patent term extension of U.S. Patent No. 5,435,989 based upon the human drug product DaunoXome® was filed by patent owner NeXstar Pharmaceuticals, Inc. in the Patent and Trademark Office on June 7, 1996. Applications for patent term extension of 5,019,369 and 5,441,745, based upon the same product, were also filed on June 7, 1996.

On January 26, 1998, the PTO mailed a Notice of Final Determination in all of the above-noted applications informing NeXstar that the patents qualify for patent term extension but for the fact that pursuant to 35 U.S.C. § 156(c)(4), only one patent may be extended for the same regulatory review period for a product. NeXstar was given a period of one-month to elect the patent for which term extension is desired.

On February 18, 1998, NeXstar filed a paper electing to have the term of U.S. Patent No. 5,441,745 extended. Accordingly, the application for patent term extension of the term of U.S. Patent No. 5,435,989 is dismissed under 35 U.S.C. 156(c)(4).

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

  
Karin Tyson  
Senior Legal Advisor  
Special Program Law Office  
Office of the Deputy Assistant Commissioner  
for Patent Policy and Projects

cc: Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 15-22  
Rockville, MD 20857

RE: DaunoXome®  
FDA Docket No.: 96E-0289